AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Biospace

Published November 6, 2026 · Updated November 7, 2026

Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational ...

Read the full story at Biospace

Middle East and Africa at Ultragenyx. “We recognise the profound ... Psychedelics · Compass to submit psilocybin depression drug for approval.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelics middle east